How anti-TB drugs pass into breast milk
Treatments studied
Part of Infections clinical trials.
This study looks at how anti-tuberculosis (TB) medicines move into breast milk and stay in the body of breastfeeding women. The goal is to learn more about the safety and dosing of these drugs for mothers and their babies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy woman aged 18 or older.
- You are breastfeeding and it has been between 3 months and 24 months since giving birth.
- Your baby is healthy.
- You are not currently diagnosed with TB infection or active TB disease.
- You weigh between 25 and 100 kg.
- You are willing to provide written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how medicines you take while breastfeeding get into your breast milk and what that might mean for your baby. It could help you understand if your medication is safe while nursing.
This study looks at how tuberculosis (TB) infection might affect the placenta and its function during pregnancy. If you are pregnant and giving birth soon, researchers want to learn if TB changes how the placenta grows and works.
This study looks at how common TB medicines are absorbed, used, and cleared in children who are already taking treatment for tuberculosis. It may help doctors choose safer and more effective doses for children.
This trial tests whether higher or standard doses of the antibiotic rifampicin work better for treating pulmonary tuberculosis (a lung infection). You may benefit if you are starting TB treatment and have not had a bad reaction to rifampicin before.
This study tests whether giving a personalized dose of rifampin (a key TB medicine) can improve treatment. It is for people with active TB that is sensitive to rifampin, and it involves frequent blood and urine tests to measure drug levels.
This study tests a daily combination of two medicines, rifapentine and isoniazid, to prevent tuberculosis (TB) in children under 13 years old. It aims to see if this short treatment is safe and works well for kids, including those living with HIV.
Hear when a new Tuberculosis Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.